Certara (NASDAQ:CERT) Upgraded to Hold at UBS Group

Certara (NASDAQ:CERT) was upgraded by investment analysts at UBS Group to a “hold” rating in a research note issued on Wednesday, Zacks reports.

A number of other brokerages have also weighed in on CERT. Weiss Ratings upgraded shares of Certara from a “sell (e+)” rating to a “sell (d)” rating in a research note on Wednesday, August 5th. Barclays increased their price target on Certara from $6.50 to $7.50 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.45.

Certara Stock Performance

Shares of CERT stock opened at $9.20 on Wednesday. The company has a 50 day moving average price of $8.19 and a 200-day moving average price of $6.72. Certara has a 52 week low of $4.45 and a 52 week high of $13.88. The firm has a market capitalization of $1.40 billion, a PE ratio of -20.44 and a beta of 1.40. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.30.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $93.27 million for the quarter, compared to analysts’ expectations of $98.09 million. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The firm’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.07 earnings per share. As a group, equities research analysts expect that Certara will post 0.22 earnings per share for the current year.

Institutional Investors Weigh In On Certara

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Central Pacific Bank Trust Division raised its stake in Certara by 8.7% during the 2nd quarter. Central Pacific Bank Trust Division now owns 19,460 shares of the company’s stock worth $127,000 after acquiring an additional 1,558 shares during the period. Sequoia Financial Advisors LLC increased its stake in shares of Certara by 12.0% in the second quarter. Sequoia Financial Advisors LLC now owns 17,906 shares of the company’s stock worth $117,000 after purchasing an additional 1,923 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Certara by 12.1% during the 1st quarter. The Manufacturers Life Insurance Company now owns 23,289 shares of the company’s stock valued at $133,000 after purchasing an additional 2,513 shares during the period. Pacer Advisors Inc. lifted its stake in shares of Certara by 28.1% during the 1st quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock valued at $75,000 after buying an additional 2,871 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Certara by 22.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 24,972 shares of the company’s stock valued at $142,000 after buying an additional 4,618 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Company Profile

Certara (NASDAQ:CERT) provides software and technology-enabled services that support the development, approval and commercialization of medicines. The company specializes in model-informed drug development, using pharmacometrics, simulation, data analysis and regulatory science to help biopharmaceutical companies evaluate drug safety, efficacy, dosing and potential regulatory outcomes.

Its software portfolio includes platforms such as Simcyp, which supports clinical pharmacology and drug-interaction modeling; Phoenix, used for pharmacokinetic and pharmacodynamic analysis; and Pinnacle 21, which helps organizations manage clinical data standards and regulatory submissions.